| BASEC ID | Project title | Type of project | Type of clinical trial | Study phase (clinical trials only) | multi- / monocentric | Category | Principal investigator | Sponsor | Investigational sites | Lead EC | Local EC(s) | Approval date | Minors | Study Ended | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2019-01716 | Conestat alfa ( a recombinant human C1 esterase inhibitor) for the prevention of acute kidney injury after non - ST elevation myocardial infarction: a randomized, double-blind, placebo control, multi More ... | clinical trial | drugs | phase 2 | multicentric | C | PD Dr. med. Michael Osthoff | Pharming Technologies B.V. |
University Hospital Basel, Basel Inselspital Bern, Bern Hôpitaux Unversitaires Geneve (HUG), Genève Fondazione Cardiocentro Ticino, Lugano |
Ethikkommission Nordwest- und Zentralschweiz EKNZ | Kantonale Ethikkommission Bern, Commission Cantonale d'éthique de la recherche Genève (CCER), Comitato etico cantonale Ticino | 28.10.2019 | Study has ended | ||